What You Should Know
– Rune Labs, the leader in precision neurology, has appointed Amy Gordon Franzen as its new Chief Executive Officer.
– Franzen, a foundational leader from Tempus, joins as Rune Labs prepares to scale its StrivePD ecosystem beyond Parkinson’s Disease into Alzheimer’s and other dementias. Co-founder Brian Pepin will transition to President, Biopharma and Platform, focusing on the company’s expanding research portfolio and life sciences partnerships.
Bringing Commercial Scale to Neurology
The appointment of Franzen is a calculated move to replicate the “precision medicine revolution” seen in oncology over the last decade. At Tempus, Franzen was instrumental in scaling a high-growth clinical trial organization and forging the biopharma partnerships that define the modern data-driven oncology landscape.
- Commercial Expansion: Franzen’s mandate is to deepen alignment with clinicians, payers, and pharma leaders to move Rune Labs from a specialized tool to a systemwide infrastructure.
- Beyond Parkinson’s: While StrivePD is the “preeminent” AI platform for Parkinson’s, the company is now extending its continuous data and AI infrastructure across the broader aging population.
- Real-World Evidence (RWE): The goal is to support scalable reimbursement pathways for digitally enabled care, providing payers and health systems with the “hard data” needed to justify new neurological interventions.
“StrivePD has already transformed how people with Parkinson’s understand and manage their disease,” said Franzen. “Our next chapter is about scale – extending the commercial and clinical infrastructure needed to deliver AI-enabled care across all neurology and more deeply integrating with trial sponsors, payers, and health systems.”
